1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Novogene Co., Ltd. Class A

Novogene Co., Ltd. Class A

SSSE:688315
19.35
CNY
+1.16
(+6.38%)
0.41EPS
31.57P/E
5.21BMarket Cap
Oct 29Next Earn
Novogene Co., Ltd. Class A
SSE:688315
(Shanghai Stock Exchange)

Recent

price

19.35

P/E

ratio

31.57

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.77
3.98
2.02
2.93
4.3
4.08
4.81
4.78
4.95
5.15
5.43
5.58
Revenue per Share
0.06
0.34
0.22
0.27
0.32
0.1
0.58
0.44
0.44
0.48
0.41
0.4
Basic EPS, GAAP
0.24
-0.28
-1.21
0.2
-0.24
0.68
0.47
0.22
0.54
0.5
0.28
- -
Free Cash Flow per Basic Share
- -
0.03
0.01
- -
0.01
0.03
0.01
0.06
0.05
0.05
0.05
- -
Dividend per Share
0.11
2.2
2.4
2.69
3.01
3.1
4.48
4.91
5.9
5.98
6.37
6.44
Book Value per Share
0.11
2.19
2.38
2.66
2.94
3.01
4.37
4.78
5.79
5.88
6.27
6.33
Tangible Book Value per Share
400
115
366
360
357
365
388
403
405
410
407
409
Basic Weighted Avg Shares
310
458
739
1,054
1,535
1,490
1,866
1,926
2,002
2,111
2,210
2,281
Sales/Revenue/Turnover
9.84
10.47
8.71
10.75
8.61
4.31
13.76
12.63
9.97
10.68
8.67
8.52
Operating Margin (%)
12
21
48
82
89
107
132
132
147
159
149
- -
Depreciation Expense
25
39
81
97
114
37
225
177
178
197
167
162
Net Income, GAAP
26.23
21.13
8.79
13.29
4.01
3.07
7.13
12.96
13.83
9.3
11.11
10.95
Effective Tax Rate (%)
8
8.54
10.89
9.22
7.45
2.45
12.07
9.2
8.89
9.32
7.56
7.1
Profit Margin (%)
-22
606
232
194
251
292
890
985
1,428
1,442
1,707
1,751
Working Capital
- -
- -
- -
- -
- -
39
29
28
17
14
36
50
LT Debt
41
793
865
972
1,087
1,121
1,798
1,976
2,474
2,513
2,681
2,709
Total Equity
- -
7.26
8.81
10.24
10.13
2.71
14.37
9.34
8.04
8.31
6.51
6.06
Return on Invested Capital (%)
- -
8.58
9.05
10.25
10.42
3.87
14.53
9.04
7.7
7.53
6.18
5.87
Return on Capital (%)
- -
9.39
9.72
10.61
11.15
3.32
15.49
9.43
8.05
7.96
6.49
6.22
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
35
40
41
LT Borrowings
- -
- -
- -
LT Finance Leases
36
29
50
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
416
416
416
Market Capitalization
5,527
5,781
5,207

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,916
2,814
2,865
Cash, Cash Equivalents & STI
1,767
1,628
1,717
Accounts Receivable, Net
600
678
681
Inventories
295
269
268
Total Current Liabilities
1,209
1,074
1,114
Payables & Accruals
- -
- -
- -
ST Debt
35
40
41
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
199.83%
20.76%
6.69%
Free Cash Flow
42.58%
4%
-44.47%
Net Income, GAAP
62.47%
98.17%
-15.16%
Sales/Revenue/Turnover
23.7%
8.5%
4.66%
Total Cash Common Dividend
144.71%
157.94%
4.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
468
528
523
592
2,111
2025
502
538
- -
629
2,210
2026
556
557
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.12
0.14
0.15
0.48
2025
0.08
0.11
- -
0.13
0.41
2026
0.07
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Novogene Co., Ltd. is a leading provider of genomic services and solutions founded in 2011 and headquartered in Beijing, China. The company specializes in next-generation sequencing (NGS) and bioinformatics services, offering a comprehensive range of products including whole genome sequencing, RNA sequencing (mRNA, lncRNA), epigenetic sequencing, metagenomic sequencing, genotyping by sequencing, de novo sequencing, resequencing, amplicon sequencing, and related bioinformatics analysis. Novogene serves a broad customer base including research universities, scientific institutions, hospitals, pharmaceutical research and development, and agricultural enterprises across Mainland China, Hong Kong, Macau, Taiwan, the US, UK, Singapore, Netherlands, Japan, and Thailand. The company operates a global network of labs and experimental facilities and supports over 4,000 customers in about 70 countries. Novogene maintains large-scale, high-throughput sequencing capacity with extensive use of advanced molecular biotechnology and high-performance computing platforms. It continues to expand its cutting-edge sequencing technology, exemplified by the 2024 launch of Falcon III, an upgraded intelligent NGS delivery platform that automates DNA and RNA sequencing processes and doubles sample processing efficiency. The company also expanded sequencing capacity in Europe by installing additional Illumina NovaSeq X Plus systems and introduced the PacBio Kinnex Full-Length RNA sequencing service enhancing RNA sequencing capabilities. Novogene’s recent developments reflect a strategic emphasis on automation, efficiency, and expanding geographic and technological reach within the genomics and life sciences sectors. Novogene is publicly listed on the Shanghai Stock Exchange (ticker 688315.SS) and has a diversified portfolio of subsidiaries and research centers globally. It holds numerous patents and software copyrights, reinforcing its leadership in genomics services and research innovation. The company focuses on integrating genomic data with cutting-edge bioinformatics to support medical, agricultural, and environmental research, strengthening its position as a global biotechnology service provider. Its latest strategic expansions and product launches support its mission to drive scientific advancement through molecular biotechnology and comprehensive genetic analysis solutions.